Testosterone is the foundation. Trenbolone is the amateur’s idea of hardcore. Beyond that lies a class of compounds that were never meant to be touched by the public. Shut down not because they failed, but because they worked too well. These are the tools that delete natural limits.
A decoy receptor that binds and neutralizes myostatin, activin A, and related growth inhibitors. In animal models, lean mass increased by up to 30% in weeks. In primates, 20%. In human trials, 5–10% lean mass gain in under a month, with no training. Trials were quietly halted after minor side effects like vascular dilation and elevated hematocrit.
Extrapolated human dose: 60–120 mg/week, subcutaneous
Outcome: Rapid hypertrophy, minimal fat gain, strong rebound on cessation
Risk: Elevated BP, potential fibrosis with abuse, systemic overgrowth at high doses
Ref: Targeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction
An anti-myostatin monoclonal antibody from Regeneron. Safer and more specific than ACVR2B-Fc. Effective in clinical settings, increasing muscle mass in sarcopenic patients. Never brought to market. Not due to inefficacy, but because it bypassed the slow, profitable path of traditional treatment.
Ref: Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice
Not a drug, rather a rewrite. AAV vectors deliver a permanent override to the body’s catabolic controls. Monkeys receiving AAV1-FS344 developed visible hypertrophy across muscle groups. Human trials showed 15–25% muscle growth in injected areas. In underground applications, systemic use is already standard.
Effect: Long-lasting hypertrophy, significant strength increase, hard to reverse
Risk: Immune response, systemic organ effects, total lack of off-switch
Ref: Follistatin gene delivery enhances muscle growth and strength in nonhuman primates
Marketed as an injectable version of gene therapy. Frequently underdosed or counterfeit. Active formulations produce results comparable to ACVR2B-Fc, but consistency is nonexistent. Risk profile is undefined because no one tracks the fallout.
Available through unregulated biotech networks. FS344 plasmids, CRISPR payloads, and viral vectors packaged for off-label human enhancement. Use is increasing among top-tier bodybuilders, cash-flush biohackers, and private labs with no regard for regulatory limits.
Effect: Full-spectrum muscle control manipulation
Risk: Unknown, permanent, and often ignored
Ref: CRISPR/Cas9-Targeted Myostatin Deletion Improves the Myogenic Differentiation Parameters for Muscle-Derived Stem Cells in Mice
Eterna clinic in Dubai offers some gene therapy: https://eterna.health/services/follistatin-gene-therapy
Also Garm in Roatan and Nassau: https://www.garmclinic.com/#gene-therapy
These are not performance enhancers. They’re growth triggers that operate outside the traditional hormone axis. The gains are rapid, disproportionate, and often permanent. These tools were buried to preserve the illusion of control: not because they failed, but because they delivered results too fast for the market to monetize.
• Testosterone — baseline enhancement
• Trenbolone — brute-force synthetic drive
• ACVR2B-Fc — targeted growth disinhibition
• Follistatin gene therapy — biological rule rewrite
• Gene doping — full override of natural regulation
ACVR2B-Fc (ActRIIB-Fc)
A decoy receptor that binds and neutralizes myostatin, activin A, and related growth inhibitors. In animal models, lean mass increased by up to 30% in weeks. In primates, 20%. In human trials, 5–10% lean mass gain in under a month, with no training. Trials were quietly halted after minor side effects like vascular dilation and elevated hematocrit.
Extrapolated human dose: 60–120 mg/week, subcutaneous
Outcome: Rapid hypertrophy, minimal fat gain, strong rebound on cessation
Risk: Elevated BP, potential fibrosis with abuse, systemic overgrowth at high doses
Ref: Targeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction
REGN1033
An anti-myostatin monoclonal antibody from Regeneron. Safer and more specific than ACVR2B-Fc. Effective in clinical settings, increasing muscle mass in sarcopenic patients. Never brought to market. Not due to inefficacy, but because it bypassed the slow, profitable path of traditional treatment.
Ref: Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice
Follistatin-344 Gene Therapy (AAV1-FS344)
Not a drug, rather a rewrite. AAV vectors deliver a permanent override to the body’s catabolic controls. Monkeys receiving AAV1-FS344 developed visible hypertrophy across muscle groups. Human trials showed 15–25% muscle growth in injected areas. In underground applications, systemic use is already standard.
Effect: Long-lasting hypertrophy, significant strength increase, hard to reverse
Risk: Immune response, systemic organ effects, total lack of off-switch
Ref: Follistatin gene delivery enhances muscle growth and strength in nonhuman primates
Follistatin-344 Peptide (black market)
Marketed as an injectable version of gene therapy. Frequently underdosed or counterfeit. Active formulations produce results comparable to ACVR2B-Fc, but consistency is nonexistent. Risk profile is undefined because no one tracks the fallout.
Gene Doping Kits
Available through unregulated biotech networks. FS344 plasmids, CRISPR payloads, and viral vectors packaged for off-label human enhancement. Use is increasing among top-tier bodybuilders, cash-flush biohackers, and private labs with no regard for regulatory limits.
Effect: Full-spectrum muscle control manipulation
Risk: Unknown, permanent, and often ignored
Ref: CRISPR/Cas9-Targeted Myostatin Deletion Improves the Myogenic Differentiation Parameters for Muscle-Derived Stem Cells in Mice
Eterna clinic in Dubai offers some gene therapy: https://eterna.health/services/follistatin-gene-therapy
Also Garm in Roatan and Nassau: https://www.garmclinic.com/#gene-therapy
These are not performance enhancers. They’re growth triggers that operate outside the traditional hormone axis. The gains are rapid, disproportionate, and often permanent. These tools were buried to preserve the illusion of control: not because they failed, but because they delivered results too fast for the market to monetize.
HIERARCHY OF MASS
• Testosterone — baseline enhancement
• Trenbolone — brute-force synthetic drive
• ACVR2B-Fc — targeted growth disinhibition
• Follistatin gene therapy — biological rule rewrite
• Gene doping — full override of natural regulation
Last edited:
